Absci Advances ABS-201 Into Phase I/IIa
Absci Corporation told investors at KeyBanc's Virtual Health Care Forum on March 17, 2026 that it uses generative AI and a lab-in-the-loop process to design antibody-based therapeutics and is advancing AI-designed molecules into the clinic. Its lead program, ABS-201, an AI-designed antibody targeting the prolactin receptor, shows favorable developability and is currently in a Phase I/IIa study, marking clinical validation steps for its platform.
Key Points
- 1Advance ABS-201 into Phase I/IIa testing, AI-designed antibody targeting the prolactin receptor
- 2Leverage generative AI and lab-in-the-loop to reduce design cycle and improve developability
- 3Enable practitioners to deploy AI-designed biologics with potential faster clinic progression and manufacturability
Scoring Rationale
Company-verified clinical progression supports credibility; limited novelty and shallow disclosure constrain broader industry impact overall.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems